,0
symbol,AVRO
price,16.0
beta,0.0
volAvg,181987
mktCap,583216000
lastDiv,0.0
range,9.76-29.32
changes,0.36
companyName,AVROBIO Inc
currency,USD
cik,0001681087
isin,US05455M1009
cusip,05455M100
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,http://www.avrobio.com
description,"Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 73 full-time employees. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The firm is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Companyâ€™s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The firm is developing AVR-RD-04 for the treatment of patients with cystinosis."
ceo,Mr. Geoff MacKay
sector,Healthcare
country,US
fullTimeEmployees,112
phone,17819626030
address,1 Kendall Sq Bldg 300 Ste 201
city,Cambridge
state,MASSACHUSETTS
zip,02139
dcfDiff,
dcf,22.3483
image,https://financialmodelingprep.com/image-stock/AVRO.png
ipoDate,2018-06-21
defaultImage,False
